Long-term Survival Analysis From PERLA, A Phase II Randomized Trial of Dostarlimab With Chemotherapy Versus Pembrolizumab With Chemotherapy in Metastatic Nonsquamous NSCLC

Introduction: PERLA is a global, double-blind, phase II trial comparing anti–programmed cell death protein 1 antibodies, dostarlimab, and pembrolizumab in combination with chemotherapy (D+CT and P+CT, respectively) in patients with metastatic nonsquamous NSCLC without actionable genomic aberrations...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Sun Min Lim, MD, PhD, Ana Laura Ortega Granados, MD, Gustavo dix Junqueira Pinto, MD, MSc, Christian Sebastián Fuentes, MD, Giuseppe Lo Russo, MD, Michael Schenker, MD, Jin Seok Ahn, MD, PhD, Filippo de Marinis, MD, Kenneth Locke, Jr., PhD, Zsolt Szijgyarto, PhD, Elena Buss, MSc, Neda Stjepanovic, MD, PhD, Ivan Diaz-Padilla, MD, PhD, Solange Peters, MD, PhD
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-10-01
Edice:	JTO Clinical and Research Reports
Témata:	Dostarlimab Pembrolizumab NSCLC PD-1 receptor Immune checkpoint inhibitors
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666364325001183
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!